AOD 9604 – 5MG

AOD 9604 peptide (AOD stands for Advanced Obesity Drug) is a modified form of growth hormone developed to help combat obesity by enhancing fat breakdown. It is a modified fragment of growth hormone in which the last 16 amino acids (176-191) have been reproduced as a specific peptide known as GH Fragment 176-191 or AOD 9604. It also has a tyrosine residue in place of the N-terminus first amino acid, which according to researchers believe can increase the stability of the peptide.

To clarify, the lipolytic fragment of GH appears to be a smaller region of the whole molecule, and AOD 9604 is not this part of the GH molecule. For example, according to the same studies “the N-terminal region shows insulin-potentiating activity and amino acids 108–129 of hGH were identified as responsible for high mitogenic activity.

Overview

Developed in the 1990s as a derivative of the hGH, AOD 9604 peptide was developed to create proteins that could facilitate anti-obesity activity. Finicky scientific tests and trials have hence been held to detect the probable demeanor of AOD 9604 in lipolysis. Lipolysis: A process through which stored fats or triglycerides in fat cells are broken down into glycerol and free fatty acids, which can then be used as an energy source by other cells. It appears that enzymes including lipase play a key role in this process and breakdown these fats. There are also areas in the body where AOD 9604 may impact fat cells and lipolytic receptors, especially as it has been found to correlate with weight and fat loss in mice. Results of studies suggest that introduction of the fragment seems to provide an increase in lipolytic sensitivity at the site following administration. In addition, the study suggests a possible interaction of AOD 9604 with the beta-adrenergic pathway, in particular regarding the beta(3)-adrenergic receptors (beta(3)-AR) that are believed to be critical lipolytic receptor residing in fat cells. Although less consistent, beta(3)-AR RNA which is the major lipolytic receptor in fat cells was also reported increased under the influence of AOD 9604. Perhaps that could mean the peptide might have some kind of role in sensitizing these lipolytic receptors or just making them more willing to lipolytic stimuli. Nevertheless, it is important to state that although the peptide seems to increase the beta(3)-AR, this increment may not be as a direct result of the peptide and cannot colonize exerts its lipolytic stimulation carcass straight during Blubber 9.

Scientist and researchers have hypothesized that the tail end of the 191 amino-acid sequence in hGH is responsible for many of its regenerative properties. AOD 9604 is an exact replica of an 18-amino-fragment that falls to the C-terminus or last region of human Growth Hormone, this region nonetheless has portrayed one of its most potent effects when increased Glycolysis or sugar metabolism/breakdown during resulted in fat burning process (normal people stimulate the production of Insulin-like Growth Factor IGF 1 but do not offer benefits on muscle growth or resistance, which is why some scientists believe 264 fragment acts on a site apart from common cells for this preserved peptide); so maybe it may be likely, over time and if used adequately with limited doses and cycles, AOD 9604 could avoid reduced responses to dieting and exercise until patients lose existent excess body weight and reach full response ranges; no validity was still reported for other effective actions yet at present screening could be considered preliminary.

THE CONTENT ON THIS WEBSITE IS STRICTLY INFORMATIONAL. IT IS NOT INTENDED TO BE TAKEN AS MEDICAL ADVICE OR AS A SCIENTIFIC PUBLICATION.

None of the products have been evaluated by The Food and Drug Administration, and are not for medical use. Their use in human or animal subjects is strictly prohibited by law, and they are available here only for in-vitro research purposes, by licensed professionals. By purchasing from this site, you agree to comply with our Terms and Conditions.